Filing Flows

Filing Flows › Companies › Aclaris Therapeutics › Cash flow

Aclaris Therapeutics cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$24.1M in Q3 2026 · −$75.3M over twelve months

Operating cash flow−$24.1M
Capital spending−$13K
Free cash flow−$24.1M

Analysis

In Q3 2026, Aclaris Therapeutics generated −$24.1M of operating cash flow and spent $13K on capital projects, leaving free cash flow of −$24.1M. That is $13.1M less than in Q3 2025 (−$11.0M).

Over the twelve months to Sep 30, 2026, operating cash flow was −$75.2M; the largest uses were operating cash flow ($75.2M), other investing ($43.4M), taxes on employees’ shares ($498K); besides operations, cash came from other financing ($114M); the cash balance fell by $4.9M.

Operating cash flow was −$24.1M against net income of −$18.5M. The largest differences: payables −$6.5M, stock-based pay +$3.0M, accrued liabilities +$2.3M.

Free cash flow

Aclaris Therapeutics: free cash flow by quarterAclaris Therapeutics: free cash flow by quarter−$8.9MQ4 2024−$13.1MQ1 2025−$10.0MQ2 2025−$11.0MQ3 2025−$13.2MQ4 2025−$18.2MQ1 2026−$19.9MQ2 2026−$24.1MQ3 2026
Operating cash flow less capital spending.
Aclaris Therapeutics: operating cash flow against capital spendingAclaris Therapeutics: operating cash flow against capital spendingOperating cash flowCapital spending−$8.9M$0Q4 2024−$13.1M$43KQ1 2025−$10.0M$21KQ2 2025−$10.9M$23KQ3 2025−$13.1M$24KQ4 2025−$18.1M$13KQ1 2026−$19.8M$58KQ2 2026−$24.1M$13KQ3 2026
Latest (Q3 2026): Operating cash flow −$24.1M, Capital spending $13K.

Capital allocation, year by year

Aclaris Therapeutics: where the cash came from (up) and went (down), by fiscal yearAclaris Therapeutics: where the cash came from (up) and went (down), by fiscal yearOperating cash flowShares issuedCapital spendingFY2021: Operating cash flow −$52.1MFY2021: Shares issued $1.5MFY2021: Capital spending −$308K$1.5MFY2021FY2022: Operating cash flow −$67.6MFY2022: Shares issued $157KFY2022: Capital spending −$605K$157KFY2022FY2023: Operating cash flow −$78.3MFY2023: Shares issued $94KFY2023: Capital spending −$1.3M$94KFY2023FY2024: Operating cash flow −$20.1MFY2024: Shares issued $32KFY2024: Capital spending −$121K$32KFY2024FY2025: Operating cash flow −$47.1MFY2025: Capital spending −$111KFY2025
Over these 5 years operating cash flow totalled −$265M; the largest uses were operating cash flow ($265M) and capital spending ($2.5M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$114M
Debtnone
Net cash$114M
Cash runway18 months

Aclaris Therapeutics is burning cash: its operations consume cash, a free cash flow of −$75.3M a year at the current rate against $114M of cash and investments: a runway of about 18 months before any new financing.

Where the cash came from and went

Aclaris Therapeutics: sources (+) and uses (−) of cash, Q3 2026Aclaris Therapeutics: sources (+) and uses (−) of cash, Q3 2026Other financing$58.4MOther investing−$33.2MOperating cash flow−$24.1MCash drawn (+) / kept (−)−$1.2MShares issued$223KTaxes on employees’ shares−$63KCapital spending−$13K
Aclaris Therapeutics: sources (+) and uses (−) of cash, TTM to Q3 2026Aclaris Therapeutics: sources (+) and uses (−) of cash, TTM to Q3 2026Other financing$114MOperating cash flow−$75.2MOther investing−$43.4MCash drawn (+) / kept (−)$4.9MTaxes on employees’ shares−$498KCapital spending−$108K

From profit to cash

Aclaris Therapeutics: net income to operating cash flow, Q3 2026Aclaris Therapeutics: net income to operating cash flow, Q3 2026Net income−$18.5MDepreciation & amortization$100KStock-based pay$3.0MPayables−$6.5MAccrued liabilities$2.3MDeferred revenue−$985KOperating cash flow−$24.1M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q2 202511—1339-1327
Q1 202518—982-965
Q4 20243—806-803

Every quarter

QuarterOperating cash flowCapital spendingShares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026−$24.1M−$13K$223K−$1.2M−$24.1M
Q2 2026−$19.8M−$58K$114K$9.5M−$19.9M
Q1 2026−$18.1M−$13K$151K−$8.7M−$18.2M
Q4 2025−$13.1M−$24K—$5.3M−$13.2M
Q3 2025−$10.9M−$23K—$146K−$11.0M
Q2 2025−$10.0M−$21K—$5.0M−$10.0M
Q1 2025−$13.1M−$43K—−$5.8M−$13.1M
Q4 2024−$8.9M——$23.1M−$8.9M

Aclaris Therapeutics: income statement and cash flow

Aclaris Therapeutics, Q3 2026: revenue $1.5M (-55% year over year). The chart follows the revenue to costs, profit and cash.

Aclaris Therapeutics: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.